Report
Patrik Ling
EUR 92.48 For Business Accounts Only

Elekta (Hold, TP: SEK90.00) - Soft Q2 gross margin

Reported Q2 earnings overall were in line or better than our forecast. The earnings beat (c7% above consensus on adj. EBIT and 3% above our estimate) was driven by lower operating expenses, with the largest deviation seen in R&D expenses, where the capitalisation of R&D costs was above our forecast. The gross margin missed our estimate by 220bp and consensus by 230bp. Order intake was in line with consensus but c3% below our forecast. We reiterate our HOLD but have trimmed our target price to SEK90 (92).
Underlying
Elekta AB Class B

Elekta AB is a human care company providing clinical solutions for treating cancer and brain disorders. Co. develops tools and treatment planning systems for radiation therapy including brachytherapy and radiosurgery, as well as workflow improving software systems across the field of cancer care. Co. has four product areas: Elekta Neuroscience, which develops solutions for the diagnosis and treatment of neurological diseases; Elekta Oncology, which develops clinical solutions for radiation therapy, imaging systems and clinical solutions for patient positioning and immobilization; Elekta Brachytherapy, which is engaged in cancer treatment based on internal radiation; and Elekta Software.

Provider
DnB Markets
DnB Markets

DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.

 

Analysts
Patrik Ling

Other Reports on these Companies
Other Reports from DnB Markets

ResearchPool Subscriptions

Get the most out of your insights

Get in touch